ERBB2 and breast carcinoma: Sandberg and co-authors [30] have formulated the following criteria for the selection of a reference tissue for the determination of HER2 status by affibody-mediated imaging: (1) correlation with data from biopsy analysis; (2) low variation in tracer uptake; (3) low probability of homing breast cancer metastases.